Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

However, the importance of detailed cognitive phenotyping in patients without dementia when interpreting p-tau217 results remains unclear. Results A total of 776 participants from the MEMENTO cohort (N = 2323 participants) and 193 participants from the BALTAZAR cohort (N = 1040) were included in this analysis. Replicated analyses in the BALTAZAR cohort provided similar results. Conclusions and relevance Results from 2 clinical cohorts suggest that amyloid prevalence varied across cognitive phenotypes and was associated with the diagnostic performance of blood p-tau217 models to determine brain amyloidosis.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 2,323 participants. In two clinical cohorts, the prevalence of amyloid varied across cognitive phenotypes and this was associated with how well blood p-tau217 models detected brain amyloid. Reported effect size: 16.5%; 45.9%; 24.5%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bouteloup, V., Villain, N., Vidal, J. S., Gonzalez-Ortiz, F., Yuksekel, I., Santos, C., et al. (2025). Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers. JAMA neurology. https://doi.org/10.1001/jamaneurol.2025.0142

Vancouver

Bouteloup V, Villain N, Vidal JS, Gonzalez-Ortiz F, Yuksekel I, Santos C, et al. Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers. JAMA neurology. 2025. doi:10.1001/jamaneurol.2025.0142. PMID: 40181683.

BibTeX

@article{bouteloup2025-40181683,
  author  = {Bouteloup, V. and Villain, N. and Vidal, J. S. and Gonzalez-Ortiz, F. and Yuksekel, I. and Santos, C. and Schraen-Maschken, S. and Pellegrin, I. and others},
  title   = {{Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.0142},
  pmid    = {40181683},
  url     = {https://doi.org/10.1001/jamaneurol.2025.0142}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In two clinical cohorts, the prevalence of amyloid varied across cognitive phenotypes and this was associated with how well blood p-tau217 models detected brain amyloid. This concerns how to interpret a blood test, not a treatment, cure or prevention.

Study details

How this study scored 70/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 70 of 100.70 of 100 points earned30 not earned

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 3 / 4 2,323 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 35 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 11.7 citations a year over 3 year(s) since 2025
Impact for its field and year 5 / 6 Cited 22.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 5 other studies in this library
Still being cited 2 / 4 Cited 35 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Christine Delmaire: h-index 48 (OpenAlex, whole career)
Institution's track record 3 / 3 Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 20 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40181683)
Free to read 2 / 2 Free to read
Total 70 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →